Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR 883.50
+22.00 (2.55%)
Jan 23, 2026, 3:29 PM IST
Alivus Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2020 |
| 25,123 | 23,869 | 22,832 | 21,612 | 21,232 | 18,852 | Upgrade | |
Revenue Growth (YoY) | 10.48% | 4.54% | 5.64% | 1.79% | 12.63% | 22.63% | Upgrade |
Cost of Revenue | 11,282 | 11,308 | 10,399 | 10,469 | 10,677 | 9,342 | Upgrade |
Gross Profit | 13,840 | 12,561 | 12,433 | 11,144 | 10,555 | 9,509 | Upgrade |
Selling, General & Admin | 2,799 | 2,705 | 2,701 | 1,896 | 1,744 | 1,553 | Upgrade |
Other Operating Expenses | 3,211 | 3,012 | 2,976 | 2,819 | 2,643 | 2,005 | Upgrade |
Operating Expenses | 6,722 | 6,323 | 6,212 | 5,136 | 4,766 | 3,892 | Upgrade |
Operating Income | 7,119 | 6,238 | 6,221 | 6,008 | 5,789 | 5,617 | Upgrade |
Interest Expense | -53.23 | -24.14 | -15.46 | -5.47 | -279.62 | -875.47 | Upgrade |
Interest & Investment Income | 200.13 | 200.13 | 120.21 | 157.66 | 67.81 | 4.3 | Upgrade |
Currency Exchange Gain (Loss) | 35.79 | 35.79 | -6.37 | 130.23 | 76.04 | -34.59 | Upgrade |
Other Non Operating Income (Expenses) | 165.14 | 33.63 | 0.21 | 1.68 | 3.19 | 3.81 | Upgrade |
EBT Excluding Unusual Items | 7,467 | 6,483 | 6,320 | 6,292 | 5,657 | 4,715 | Upgrade |
Gain (Loss) on Sale of Investments | 76.15 | 76.15 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -18.21 | -18.21 | -7.04 | -5.58 | -7.43 | -5.84 | Upgrade |
Pretax Income | 7,268 | 6,541 | 6,313 | 6,286 | 5,649 | 4,709 | Upgrade |
Income Tax Expense | 1,831 | 1,685 | 1,604 | 1,616 | 1,462 | 1,194 | Upgrade |
Net Income | 5,437 | 4,856 | 4,709 | 4,670 | 4,187 | 3,516 | Upgrade |
Net Income to Common | 5,437 | 4,856 | 4,709 | 4,670 | 4,187 | 3,516 | Upgrade |
Net Income Growth | 23.09% | 3.13% | 0.84% | 11.52% | 19.10% | 12.29% | Upgrade |
Shares Outstanding (Basic) | 123 | 123 | 123 | 123 | 118 | 108 | Upgrade |
Shares Outstanding (Diluted) | 123 | 123 | 123 | 123 | 118 | 108 | Upgrade |
Shares Change (YoY) | 0.01% | 0.17% | 0.13% | 4.25% | 9.03% | - | Upgrade |
EPS (Basic) | 44.33 | 39.63 | 38.43 | 38.11 | 35.63 | 32.61 | Upgrade |
EPS (Diluted) | 44.23 | 39.52 | 38.38 | 38.11 | 35.63 | 32.61 | Upgrade |
EPS Growth | 23.09% | 2.97% | 0.71% | 6.97% | 9.26% | 12.29% | Upgrade |
Free Cash Flow | - | 2,253 | 2,845 | 1,432 | 4,654 | 3,201 | Upgrade |
Free Cash Flow Per Share | - | 18.34 | 23.19 | 11.69 | 39.60 | 29.69 | Upgrade |
Dividend Per Share | - | 5.000 | 22.500 | 21.000 | 21.000 | - | Upgrade |
Dividend Growth | - | -77.78% | 7.14% | - | - | - | Upgrade |
Gross Margin | 55.09% | 52.63% | 54.45% | 51.56% | 49.71% | 50.44% | Upgrade |
Operating Margin | 28.34% | 26.13% | 27.25% | 27.80% | 27.27% | 29.80% | Upgrade |
Profit Margin | 21.64% | 20.35% | 20.62% | 21.61% | 19.72% | 18.65% | Upgrade |
Free Cash Flow Margin | - | 9.44% | 12.46% | 6.63% | 21.92% | 16.98% | Upgrade |
EBITDA | 7,728 | 6,788 | 6,691 | 6,394 | 6,141 | 5,940 | Upgrade |
EBITDA Margin | 30.76% | 28.44% | 29.31% | 29.58% | 28.92% | 31.51% | Upgrade |
D&A For EBITDA | 609.68 | 549.75 | 469.84 | 386.04 | 351.91 | 322.9 | Upgrade |
EBIT | 7,119 | 6,238 | 6,221 | 6,008 | 5,789 | 5,617 | Upgrade |
EBIT Margin | 28.34% | 26.13% | 27.25% | 27.80% | 27.27% | 29.80% | Upgrade |
Effective Tax Rate | 25.19% | 25.76% | 25.41% | 25.71% | 25.88% | 25.35% | Upgrade |
Revenue as Reported | 25,600 | 24,215 | 22,953 | 21,902 | 21,379 | 18,860 | Upgrade |
Advertising Expenses | - | 183.7 | 115.47 | 90.07 | 54.96 | 60.55 | Upgrade |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.